Related Experiment Video
Updated: May 4, 2026

Laparoscopic Radical Gastrectomy for Remnant Gastric Cancer
Published on: October 31, 2025
Endoscopic resection of gastric neoplasm in solid-organ transplant recipients
Shin Na1, Gin Hyug Lee, Ju Hyung Song
11 Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Asan Digestive Disease Research Institute, Seoul, Korea. 2 Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Asan Medical Center, Korea. 3 Address correspondence to: Gin Hyug Lee, M.D., Ph.D., Department of Gastroenterology, University of Ulsan College of Medicine Asan Medical Center, Asan Digestive Disease Research Institute, 388-1 Pungnap-2 dong, Songpa-gu, Seoul, 138-736, Korea.
Background:
The aim of this study was to investigate the feasibility and safety of endoscopic resection of gastric neoplasm in solid-organ transplant (SOT) recipients.
Methods:
Between January 1994 and December 2011, the results of endoscopic resection of 17 lesions in 15 consecutive patients who had previously undergone SOT at Asan Medical Center were retrospectively evaluated. We compared clinical outcomes of this group with 1:5 matched non-SOT patients treated by endoscopic resection.
Results:
Of the 6,491 patients who underwent SOT during the study periods, 30 patients (0.46%) with 31 lesions were diagnosed with gastric cancer, and eight patients (0.12%) with nine lesions were diagnosed with gastric adenoma. Among them, 15 patients with 17 lesions were treated by endoscopic resection, and 19 patients with 20 lesions have undergone gastrectomy. In endoscopically resected SOT group, the median duration between transplantation and endoscopic treatment was 41 months (range, 5-196 months). En bloc and complete resection were achieved in 13 (76.5%) and 15 (88.2%) lesions. Four lesions (23.5%) experienced bleeding, which was successfully managed endoscopically. When compared with post-endoscopic resection bleeding rate of non-SOT group (5.9%, [5/85]), there was no significant difference in multivariable analysis (P=0.083).
Conclusions:
In endoscopic resection for gastric neoplasm of SOT recipients, only manageable complications were noted in some patients, and graft dysfunctions or perforations did not occur. To avoid surgical resection with its associated perioperative mortality and morbidity, endoscopic resection for gastric neoplasm in SOT recipients is recommended as a feasible treatment with high efficacy and safety.
Insights
Endoscopic resection of gastric neoplasm is safe and effective for solid-organ transplant (SOT) recipients. This minimally invasive procedure offers high efficacy with manageable complications, avoiding surgical risks.
Area of Science:
- Gastroenterology
- Transplant Surgery
- Oncology
Background:
- Solid-organ transplant (SOT) recipients face unique challenges regarding gastric neoplasm management.
- Assessing the safety and feasibility of endoscopic resection in this population is crucial.
Purpose of the Study:
- To evaluate the feasibility and safety of endoscopic resection for gastric neoplasm in SOT recipients.
- To compare outcomes with non-SOT patients undergoing similar procedures.
Main Methods:
- Retrospective analysis of 17 gastric neoplasm resections in 15 SOT patients (1994-2011).
- Comparison with a 1:5 matched cohort of non-SOT patients.
- Evaluation of clinical outcomes, including complication rates.
Main Results:
- Endoscopic resection was achieved in 15 SOT patients with 17 lesions.
- En bloc and complete resection rates were 76.5% and 88.2%, respectively.
- Bleeding occurred in 23.5% of lesions but was managed endoscopically, with no significant difference compared to non-SOT patients.
Conclusions:
- Endoscopic resection of gastric neoplasm in SOT recipients is feasible and safe, with only manageable complications observed.
- Graft dysfunction or perforation did not occur.
- This approach is recommended to avoid surgical morbidity and mortality.
More Related Videos
06:43Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
05:16Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022